Dupilumab De-escalation in Pediatric Atopic Dermatitis

Inclusion Criteria:

* Aged 1 to \<18 years old, either sex, any race or ethnicity
* Provide signed informed consent by parent or legal guardian and informed assent if applicable
* Has a physician confirmed diagnosis of atopic dermatitis
* Has received dupilumab for at least 12 months for the treatment of atopic dermatitis
* Has had well-controlled atopic dermatitis on dupilumab within last 6 months (defined as POEM\<=7, EASI\<=7, or IGA\<=2)
* Able to speak English
* Able and willing to adhere to all study procedures

Exclusion Criteria:

* Taking concurrent systemic medication for atopic dermatitis (e.g., methotrexate, cyclosporine, tralokinumab, abrocitinib, upadacitinib, systemic corticosteroids)
* Using concurrent phototherapy for atopic dermatitis
* Taking dupilumab for a clinical indication other than atopic dermatitis (such as asthma or eosinophilic esophagitis)
* Poor control of atopic dermatitis
* Poor control of asthma or eosinophilic esophagitis
* Has used an investigational drug within 90 days or plan to use an investigational drug during the study period
* Does not have health insurance or will lose health insurance during the study period